🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — August 24, 2026

The sole contract in this digest is a $239.3 million cost-plus-fixed-fee award from NASA Ames Research Center to Amentum Technology, Inc. for aerospace testing and facilities operations, representing a fully civilian (non-defense) obligation. The contract's performance period (2016-2022) has ended, and with $120 million already outlaid, the revenue is largely realized, limiting forward-looking investment implications. The highest-conviction signal is the low pricing risk due to the cost-plus structure, which ensures predictable margins for Amentum, but the contract's age and near-completion reduce its materiality. Key watch items include any recompete for the ATOM-4 services at NASA Ames and shifts in NASA's facilities outsourcing strategy.

1 total filings
· daily

All NASA Contracts — August 24, 2026

The sole NASA contract analyzed, a $239.3M cost-plus-fixed-fee award to Amentum Technology, Inc. for facilities operations at Ames Research Center, is a legacy award (2016-2022) with no forward-looking investment catalyst. As a fully civilian, competed contract now near completion, it provides no actionable signal for defense sector exposure or near-term revenue growth. The neutral signal (5/10 strength, 4/10 materiality) and absence of any bullish or bearish signals underscore the digest's limited utility for portfolio decisions. Key risk is the lack of a recompete trigger, making this a non-event for institutional investors focused on current procurement trends.

1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 24, 2026

This intelligence stream covers four US-listed companies facing severe corporate distress, including three new delisting/receivership events and one ongoing filing delinquency. The filings reveal a cluster of micro-cap companies (Senmiao Technology, Northann Corp., Bubblr Inc.) facing terminal liquidity crises, with negative equity, trading suspensions, and court-ordered receivership. Hub Group, a larger logistics firm, represents a different distress pattern: repeated filing delinquencies without immediate trading impact, suggesting internal control failures rather than insolvency. The most critical development is Bubblr Inc.'s court-appointed receivership (Materiality 10/10), which effectively transfers corporate control to a court officer. Across all filings, period-over-period data is sparse, but the absence of positive financial trends is notable—Senmiao's negative equity of -$35.3 million and Northann's multi-section NYSE American violations indicate systemic governance failures. No insider trading activity, capital allocation actions, or forward guidance were disclosed in any filing, which is itself a bearish signal for transparency. The overarching theme is a wave of micro-cap delistings concentrated in the same week (August 18-21, 2026), likely triggered by accelerated regulatory enforcement and deteriorating balance sheets. Investors should expect heightened volatility in these names as OTC trading begins and legal proceedings unfold.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — August 24, 2026

This digest of 34 filings for August 24, 2026, reveals a pronounced bifurcation in corporate health: a cluster of distressed entities facing regulatory insolvency or delisting, while others execute strategic transactions like M&A and open offers. A primary theme is the wave of Nasdaq/NYSE American delisting actions targeting SPACs (Pantages Capital, Senmiao Technology, Northann Corp) and growth companies, signaling tighter exchange scrutiny amid market volatility. Conversely, mid-cap acquisitions and divestitures are prevalent, particularly in Indian industrials (Pavna Industries, Majestic Auto, HEG Limited), with buyers focusing on core businesses and unlocking value. The complete liquidation of the Hashdex Bitcoin ETF (DEFI) and the court-appointed receivership of Bubblr Inc. represent the two most extreme downside events, highlighting total capital loss scenarios. Capital allocation trends are defensive, with companies both cutting complexity (Pavna, Almondz Global) and seeking strategic growth (Martin Marietta, Blue Cloud Softech). Insider activity is minimal across filings, but management changes in HEG and Integrated Wellness signal strategic pivots. Overall, the period underscores a 'survival of the fittest' environment where regulatory compliance, strategic focus, and financial fortitude are paramount.

34 high priority 34 total filings
· daily

US SEC Filings Daily Market Digest — August 24, 2026

The August 24, 2026, filing stream reveals a market dominated by significant capital allocation events, strategic shifts, and mixed legal outcomes. Key themes include a wave of insider buying at Alibaba Group, signaling management confidence despite a major equity placement, and a notable 'going private' transaction for Utz Brands at a 91% premium. The SPAC sector shows continued stress, with YHN Acquisition I facing shareholder skepticism and Roman DBDR Acquisition Corp. II receiving a Nasdaq deficiency notice. Legal and regulatory developments are prominent, with mixed verdicts for Cytek Biosciences and Sable Offshore Corp. creating binary risk/reward scenarios. The energy and materials sector sees strategic divestitures, like Comstock Inc. selling its mining assets, while healthcare shows early-stage clinical progress from Precision BioSciences and Tiziana Life Sciences. Overall, the data points to a market where companies are actively managing their capital structures and legal exposures, with insider activity providing a clear signal of management conviction at Alibaba.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 24, 2026

Today's filing stream is dominated by a coordinated wave of insider selling at DoorDash, with six executives (including the CFO, COO, and multiple directors) unloading stock at ~$220-$225 per share over the same period, totaling over $29M in disclosed sales. This pattern, including a $16.3M sale by Director Stanley Tang, signals concentrated management conviction to reduce exposure at current levels, despite some sales being under Rule 10b5-1 plans. Outside of DoorDash, Yum! Brands' COO sold nearly 99% of their holdings in a single transaction, a severe risk flag. Chipotle's filing was unreadable and offers no actionable data. The overall sector theme is a glaring disconnect between insider selling and consumer spending narratives, presenting a bearish tactical signal for these specific names, especially DoorDash. Portfolio-level trends from period comparisons are absent in this batch, but the aggregate insider activity demands immediate attention.

9 high priority 9 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 24, 2026

The six filings from the S&P 500 Healthcare stream for August 24, 2026, are dominated by insider trading activity, revealing a stark divergence in management sentiment. The most critical signal is a massive, nearly complete divestiture by Danaher's CEO, who sold over $8.5 million in stock, reducing his personal stake to near zero—a highly bearish red flag. In contrast, Thermo Fisher's CEO executed a large option exercise and modest sale under a 10b5-1 plan, suggesting a more structured, less alarming approach. The remaining filings (Becton Dickinson, IDEXX, Medtronic) are routine tax-withholding transactions, carrying neutral sentiment. No period-over-period financial comparisons, forward-looking guidance, or capital allocation data were present in these filings, limiting the ability to identify portfolio-level revenue or margin trends. The overarching theme is a concentrated insider risk at Danaher, which overshadows the otherwise routine nature of the other filings.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — August 24, 2026

The eight filings reveal a market bifurcated between a few pockets of operational strength and a broader trend of restructuring, cash burn, and margin pressure. ConnectM Technology Solutions and Selectis Health both posted headline net income turnarounds, but these were entirely driven by non-recurring gains from discontinued operations and asset sales, masking underlying operational cash burn and revenue declines. Bio-Techne and Bridgford Foods represent two sides of a stagnant-growth coin: Bio-Techne’s flat sales and margin compression are being addressed via a major divestiture, while Bridgford’s deepening losses and rising leverage signal distress. Napco Security Technologies stands out as a genuine growth story with strong 11.4% revenue growth and expanding gross margins, though a one-time litigation charge depressed net income. The three smallest entities—Samos Energy (a pre-revenue SPAC) and Natics Corp.—remain in pre-revenue or micro-cap survival mode, offering no operational comparables. The dominant portfolio-level theme is the reliance on non-operational gains to mask underlying business deterioration, with 3 of 8 companies reporting net income driven by asset sales or discontinued operations. Insider trading data was notably absent across all filings, removing a key conviction signal. The forward-looking data is sparse, with only Bio-Techne providing clear guidance on its divestiture timeline, creating a catalyst calendar that is heavily weighted toward restructuring events rather than organic growth milestones. Capital allocation patterns are defensive: Bio-Techne is pruning assets, Bridgford is drawing on credit lines, and the SPACs are burning cash on formation costs. The actionable intelligence centers on Napco’s organic momentum versus the rest, and the risk of accounting-driven 'turnarounds' at ConnectM and Selectis Health that lack cash flow confirmation. Scheduled events are limited, but Bio-Techne’s pending sale of its Diagnostics and Spatial Biology segment is the most material catalyst on the horizon. Overall, the digest suggests a cautious stance on companies relying on one-time gains and a selective opportunity in Napco’s recurring service revenue growth. No filings were excluded as all eight fall within the broad market scope of the 'Financial Results & Earnings' stream.

8 high priority 8 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 24, 2026

The 13 enriched proxy filings for August 2026 reveal a pronounced wave of corporate distress and restructuring actions, with 6 of the 13 companies disclosing reverse stock splits and 4 SPACs/blank-check entities seeking yet another deadline extension, signaling a severe capital market bottleneck for micro-cap and troubled issuers. Period-over-period data, though sparse in these non-financial proxy statements, is inferred from insider activity and transaction data: exceptionally high dilution is projected at Adial Pharmaceuticals (legacy holders to own just 7.7% post-merger) and NEXGEL (mandated 6x share increase due to convertible note overhang), while Apollo Commercial Real Estate's liquidation plan provides a positive floor for distribution estimates ($7.75–$8.50 per share). Insider sentiment is markedly mixed, with LogicMark’s Special Committee receiving a fairness opinion showing negative equity values, yet no major insider sales are flagged, suggesting a wait-and-see approach. Forward-looking data builds a busy catalyst calendar through October and November 2026, with nine special or annual meetings concentrated in those months, and a key deadline of October 19 for NEXGEL to regain Nasdaq compliance. The overarching theme is a capital structure stress test, where equity holders are being asked to approve dilution, liquidation, or extension, with little evidence of organic growth from period-over-period comparisons.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 24, 2026

The August 24, 2026 IPO pipeline is dominated by two blank-check companies (Essential Minerals Acquisition Corp and Live Oak Acquisition Corp. VI) seeking a combined $350 million, alongside three resale registrations from cash-strapped issuers (NEXTNRG, Polar Power, and Serina Therapeutics) and one de-SPAC merger filing (OHB Pediatrics Ltd.). A critical portfolio-level pattern is the extreme financial distress among operating companies: NEXTNRG has only ~$4.5M cash (funding through Dec 1, 2026) and negative working capital, while Polar Power reports just ~$0.1M in stockholders' equity against a Nasdaq minimum of $2.5M. The blank-check IPOs offer a stark contrast with zero-operating-risk structures but carry significant dilution risks for public shareholders. No period-over-period comparisons were available as all filings are initial registrations without historical financial performance data. The most actionable insight is the imminent liquidity crisis at NEXTNRG and Polar Power, which could force distressed asset sales or reverse stock splits, creating potential short-term trading opportunities.

6 high priority 6 total filings
· daily

US Executive Officer Management Changes SEC — August 24, 2026

The August 24, 2026 executive and director change filings reveal a portfolio experiencing significant leadership turnover, with a notable undercurrent of governance risk and financial distress. Across 25 filings, we see a pattern of CFO appointments in companies with turnaround or restructuring narratives (Hormel, Ecovyst, USBC), while in the biotech sector, multiple small-cap firms are bolstering boards with seasoned dealmakers (ANI, FibroBiologics). The most critical developments include a CEO's paid administrative leave due to a governmental investigation at Grand Canyon Education, two board resignations reducing governance oversight at Allurion Technologies, and a high-risk CFO appointment at USBC who is a named defendant in multiple SVB-related litigations. Conversely, the CEO succession at Extra Space Storage and the new CCO role at Trex signal strategic depth in large-cap real estate and building products. While many filings lack period-over-period financial data, several disclose forward-looking statements, including reaffirmed guidance (Azenta), merger-completion bonuses (Twin Vee), and aggressive revenue targets (QXO). Insider activity is sparse, but the compensation structures for new executives, including sign-on bonuses and long-term incentives, provide insights into company alignment strategies. The overarching themes are high governance turnover, a search for operational and financial stability, and a distinct divide between well-capitalized companies executing successions and distressed firms facing existential threats.

25 high priority 25 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 24, 2026

The sole filing for the USA Bankruptcy & Insolvency stream on this quiet session is a highly material 8-K from Bubblr Inc. (BBLR), revealing that a U.S. District Court has appointed a Receiver for the company. This receivership represents a severe adverse regulatory action, effectively removing management's control and signaling acute financial distress. The filing provides no financial metrics, period-over-period comparisons, or forward-looking guidance, which is typical for such a sudden and extreme corporate event. The appointment of a Receiver is a precursor to potential liquidation or a forced restructuring, making this the single most critical development in the stream. The lack of any other filings underscores a very quiet session, with this event dominating the bankruptcy and insolvency landscape for the day.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 24, 2026

This edition of the USA Board Room Changes digest covers 25 filings, with a significant concentration of leadership changes spanning routine appointments, governance shake-ups, and a notable CEO succession. A key pattern emerging is the frequency of CFO transitions (5 filings) and the simultaneous departure/reduction of board seats (Allurion Technologies, Greenlane Holdings, MAKO Medical, Malibu Boats), which signals potential instability or strategic pivots in select firms. While most changes were neutral in sentiment, several carry actionable intelligence: Grand Canyon Education’s CFO leave amid an insider trading investigation is a major red flag, and USBC’s appointment of a CFO facing multiple FDIC litigations introduces high governance risk. On the opportunity side, Extra Space Storage’s well-planned CEO succession and QXO’s appointment of a seasoned President/COO to drive M&A-led growth appear positive catalysts. Period-over-period data was sparse in these event-driven filings, limiting trend analysis, but forward-looking statements (e.g., QXO’s $50B revenue target) and insider activity (e.g., Polar Power’s new board to address going-concern) provided depth. Overall, investors should focus on governance quality signals, as board composition is a leading indicator of strategic direction and risk management.

25 high priority 25 total filings
· daily

USA Insider Trading Pulse — August 24, 2026

This USA Insider Trading Pulse digest covers 50 filings from August 24, 2026, revealing a cautious to bearish tone among corporate insiders, with 20 distinct open-market sales events totaling ~$21.8M versus 9 open-market purchases for ~$5.5M, a notable 4:1 sell-to-buy dollar ratio. The most significant transactions include a Director at DoorDash selling $16.3M via a 10b5-1 plan, an EVP at Packaging Corp of America selling $3M, and the Alibaba CEO buying $4.98M of stock, which stands out as a high-conviction vote of confidence. A clear cluster of insider selling is observed at Procter & Gamble, where four senior executives, including the CFO, collectively sold ~$1.53M, potentially signaling concerns ahead of a future earnings report. Tax-withholding-for-vesting transactions provide limited directional insight, but their volume at companies like LiveRamp and NIQ Global Intelligence suggests significant equity compensation vesting. Key themes include concentrated insider selling at large-cap consumer staples (P&G) and tech-enabled logistics (DoorDash), contrasted with targeted insider buying at select technology and financial names, suggesting bifurcated sector conviction. The data does not contain direct forward-looking guidance, but insider activity patterns serve as a leading indicator for upcoming earnings and strategic shifts.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 24, 2026

The August 24, 2026, M&A and takeover filings reveal a bifurcated SPAC landscape: while two blank-check companies (Roman DBDR, Pantages Capital) face Nasdaq delisting risks due to non-compliance with listing standards, two others (Integrated Wellness, International Media) are actively pursuing or extending deadlines for business combinations. The most material event is the completed acquisition of RE/MAX Holdings by The Real Brokerage Inc., a definitive deal with a clear valuation structure and immediate delisting, marking a significant consolidation in the real estate brokerage sector. Martin Marietta Materials' strategic bolt-on acquisition of Lhoist North America adds over 2 billion tons of limestone reserves, reinforcing its specialty materials platform without disclosed financial terms. In contrast, the complete wind-down of the Hashdex Bitcoin ETF (Tidal Commodities Trust I) represents a total liquidation event with no ongoing operations, signaling a negative sentiment for the crypto-ETF space. Period-over-period comparisons are largely absent from these event-driven filings, but the forward-looking data (compliance deadlines, extension dates, merger completion) provides a clear catalyst calendar. Insider activity is limited, though the appointment of Binson Lau as Co-CEO of Integrated Wellness, who is also CEO of the merger target Btab, signals strong alignment with deal completion. Capital allocation is not a primary theme, but the RE/MAX deal structure (cash/stock election with proration) offers a unique arbitrage opportunity. Overall, the digest highlights a market where SPACs are under regulatory pressure, traditional M&A is value-accretive, and crypto-linked vehicles are being wound down.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 24, 2026

This pre-market digest covers 50 overnight SEC filings from August 23-24, 2026, revealing a market dominated by significant capital events and strategic shifts. The most impactful themes include a wave of going-private and M&A transactions (Utz Brands at a 91% premium, Modiv Industrial's deregistration, Callan JMB's asset acquisition), substantial insider buying at Alibaba ($5M CEO purchase) and 17 Education, contrasted with heavy secondary selling at Aveanna Healthcare. A notable SPAC sector stress is evident, with Roman DBDR facing Nasdaq delisting for low public holders and YHN Acquisition seeking a third extension amid high redemptions. Financial distress signals are flashing at BioXcel Therapeutics, which secured only a one-week debt extension. On the positive side, Aegon expanded its buyback by 150 million euros, and InterCure received a $77 million war damages settlement. Key period-over-period trends from the data show ConnectM Technology's revenue growing 24.2% YoY but with gross margin compression from 36.5% to 28.6%, while Holtec Nuclear's revenue declined 5.8% YoY. The mixed patent verdict for Cytek Biosciences ($56M award) and Sable Offshore's partial legal win create binary event risks. Overall, the filings suggest a market favoring cash returns and defensive positioning, with selective growth in AI-adjacent and rare disease sectors.

19 high priority 31 medium 50 total filings
· daily

Biotech Small-Cap Approvals — August 22, 2026

The August 22, 2026 biotech small-cap approval stream delivered two neutral-signal biosimilar approvals, with zero NME, zero label expansion, and no bullish or bearish signals. Glenmark Pharmaceuticals received approval for fluticasone propionate, a biosimilar entry in the respiratory/inflammatory space, while Sterinova Inc. received the nod for naloxone hydrochloride, a biosimilar targeting opioid overdose reversal. Both approvals are low-conviction, materiality-rated 5/10, with no disclosed peak sales estimates, exclusivity periods, or pricing power data. The key investment takeaway is the absence of high-value NME approvals; these fallback-type entries are incremental for each sponsor but lack the commercial differentiation or catalyst intensity to move sector-level sentiment. Investors should watch for payer contracting dynamics in the naloxone market, where generic erosion could limit Sterinova’s share.

2 total filings
· daily

NME Blockbuster Approvals — August 22, 2026

The digest covers a single FDA approval on August 19, 2026, for an undisclosed drug from Regeneron Pharmaceuticals, Inc. This is categorized as an NME with Priority Review and Orphan Drug designations, generating a bullish signal with high confidence. The approval underscores Regeneron's continued strength in developing targeted therapies for rare diseases, though the lack of disclosed commercial details (peak sales, pricing, market position) limits full investment assessment. The key risk is the absence of specific therapeutic area and indication data, which prevents clustering or competitive analysis. Overall, this event is a positive but opaque signal for Regeneron's pipeline execution.

1 total filings
· daily

Big Pharma Approvals — August 22, 2026

This period contains a single FDA approval: an NME from Regeneron Pharmaceuticals, Inc., designated with Priority Review and Orphan Drug status, representing a high-conviction bullish signal (strength 8/10, materiality 8/10). While the drug name and therapeutic area are not disclosed, the combination of NME, Priority Review, and Orphan designations typically signals a significant unmet medical need with premium pricing potential and 7-year Orphan exclusivity. The absence of any biosimilar or label expansion activity makes this a pure-play NME catalyst for Regeneron, though the lack of commercial details (peak sales, pricing, market position) limits full investment modeling. Key watch items include the drug's launch execution, payer coverage decisions, and any competitive dynamics in the undisclosed indication.

1 total filings
· daily

Orphan Drug Approvals — August 22, 2026

This digest covers a single Orphan Drug Approval on August 22, 2026, from Regeneron Pharmaceuticals. The approval is classified as a fallback type, not an NME, biosimilar, or label expansion, and carries a bullish signal with high materiality. The drug, designated as an NME with Priority Review and Orphan status, targets an undisclosed indication, with no peak sales, exclusivity, or pricing details provided. The key investment takeaway is Regeneron's continued ability to secure expedited FDA designations, signaling strong R&D execution in rare diseases, though the lack of commercial data limits valuation precision. The primary risk is the absence of disclosed market size and competitive positioning, which could obscure revenue potential and IRA exposure.

1 total filings